ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Biologics by McKesson joined a limited distribution network for ORSERDU, approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy.